Ironwood Being Split In Two: Is Move To Thwart Activist Investor Sarissa?

01 May 2018

• By Sten Stovall

Move will spin out sGC assets into solo listed group while smaller Ironwood will focus on GI diseases and abdominal pain.

Spin off — Ironwood's Split Will Spin Off sGC Assets • Source: Shutterstock

Catching investors and analysts on the hop, Cambridge, Mass.-based Ironwood Pharmaceuticals Inc. unveiled plans to separate into two publicly traded groups, in a move seen at least partly motivated by an activist investor's plans to extract more value for its shareholders.

The restructuring of Ironwood will see the spinning out of its soluble guanylate cyclase (sGC) stimulator pipeline for rare disorders into a stand-alone, publicly traded company, while the group's remaining operations of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

02 May 2025

• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

06 May 2025

• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.